Literature DB >> 25661553

Obesity and coronary artery disease: evaluation and treatment.

David Garcia-Labbé1, Emmeline Ruka2, Olivier F Bertrand1, Pierre Voisine1, Olivier Costerousse3, Paul Poirier4.   

Abstract

With the increasing prevalence of obesity, clinicians are now facing a growing population of patients with specific features of clinical presentation, diagnostic challenges, and interventional, medical, and surgical management. After briefly discussing the effect of obesity on atherosclerotic burden in this review, we will focus on strategies clinicians might use to ensure better outcomes when performing revascularization in obese and severely obese patients. These patients tend to present comorbidities at a younger age, and their anthropometric features might limit the use of traditional cardiovascular risk stratification approaches for ischemic disease. Alternative techniques have emerged, especially in nuclear medicine. Positron emission tomography-computed tomography might be the diagnostic imaging technique of choice. When revascularization is considered, features associated with obesity must be considered to guide therapeutic strategies. In percutaneous coronary intervention, a radial approach should be favoured, and adequate antiplatelet therapy with new and more potent agents should be initiated. Weight-based anticoagulation should be contemplated if needed, with the use of drug-eluting stents. An "off-pump" approach for coronary artery bypass grafting might be preferable to the use of cardiopulmonary bypass. For patients who undergo bilateral internal thoracic artery grafting, harvesting using skeletonization might prevent deep sternal wound infections. In contrast to percutaneous coronary intervention, lower surgical bleeding has been observed when lean body mass is used for perioperative heparin dose determination.
Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25661553     DOI: 10.1016/j.cjca.2014.12.008

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  10 in total

1.  Rs5498 polymorphism may be a risk factor for coronary heart disease in Chinese population: evidence from a meta-analysis involving 5537 subjects.

Authors:  Lei Cui; Shicong Jing; Xiangfen Wang; Qiang Zong; Xiao Li; Chunxiao Jiao; Lei Peng; Lin Liu; Xinmiao Xu; Mingfeng Niu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome.

Authors:  Roberto Mioni; Anna Dalla Cà; Jenni Turra; Sara Azzolini; Nadia Xamin; Luigi Bleve; Pietro Maffei; Roberto Vettor; Francesco Fallo
Journal:  Endocrine       Date:  2016-05-03       Impact factor: 3.633

Review 3.  Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease.

Authors:  Vaibhav B Patel; Saumya Shah; Subodh Verma; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

4.  Intravenous injection of microvesicle-delivery miR-130b alleviates high-fat diet-induced obesity in C57BL/6 mice through translational repression of PPAR-γ.

Authors:  Shifeng Pan; Xiaojing Yang; Yimin Jia; Yue Li; Rirong Chen; Min Wang; Demin Cai; Ruqian Zhao
Journal:  J Biomed Sci       Date:  2015-10-16       Impact factor: 8.410

5.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.

Authors:  Thomas R Einarson; Annabel Acs; Craig Ludwig; Ulrik H Panton
Journal:  Cardiovasc Diabetol       Date:  2018-06-08       Impact factor: 9.951

6.  Randomized Clinical Trial to Evaluate the Morphological Changes in the Adventitial Vasa Vasorum Density and Biological Markers of Endothelial Dysfunction in Subjects with Moderate Obesity Undergoing a Very Low-Calorie Ketogenic Diet.

Authors:  Enric Sánchez; Maria-Dolores Santos; Maitane Nuñez-Garcia; Marta Bueno; Ignacio Sajoux; Andree Yeramian; Albert Lecube
Journal:  Nutrients       Date:  2021-12-23       Impact factor: 5.717

7.  Obesity among type 2 diabetes mellitus at Sidama Region, Southern Ethiopia.

Authors:  Temesgen Bizuayehu; Tadesse Menjetta; Metsihet Mohammed
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

8.  Determination of 12 anti-obesity drugs in human plasma by a 96-well protein precipitation plate using HPLC-MS.

Authors:  Tengteng Ping; Min Zheng; Pingping Zhang; Tianhao Yan; Xufeng Miao; Ke Wang; Kaoqi Lian
Journal:  RSC Adv       Date:  2022-09-13       Impact factor: 4.036

9.  Weight changes following antidiabetic mediation use: Real-world evidence from health system data.

Authors:  Beini Lyu; Morgan E Grams; Lesley A Inker; Alex R Chang; Elizabeth Selvin; Jung-Im Shin
Journal:  Obes Sci Pract       Date:  2022-02-17

10.  Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight.

Authors:  Yan Ma; Ying Liu; Jie Xu; Yilong Wang; Yongjun Wang; Fenghe Du
Journal:  Ther Clin Risk Manag       Date:  2018-05-08       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.